[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuropathic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuropathic-pain":635},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,107,0,25,[9,48,75,102,118,142,161,184,208,242,262,288,314,338,362,386,409,434,464,485,506,529,553,586,612],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054309",false,"NCT07699770","Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial","Efficacy and Safety of Crisugabalin in Treating Neuropathic Pain Related to Neuromyelitis Optica Spectrum Disorders: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled, Exploratory Trial","TERMINATOR","\\*\\*Inclusion Criteria:\\*\\*\n\nSubjects who meet all of the following criteria will be enrolled in this study:\n\n1. Able to understand and voluntarily sign the written informed consent form;\n2. Male or female aged between 18 years (inclusive) and 75 years;\n3. Diagnosed with aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) according to the International Panel for NMO Diagnosis (IPND, 2015) criteria;\n4. Patients with comorbid neuropathic pain, DN4 ≥ 4; no change in medication dosage within the past month;\n5. Numeric Rating Scale (NRS) for pain score ≥ 4 at screening;\n6. First-time use of Crisugabalin Capsules.\n\n\\*\\*Exclusion Criteria:\\*\\*\n\nSubjects who meet any of the following criteria will not be enrolled in this study:\n\n1. Presence of peripheral neuropathy or pain unrelated to NMOSD that, in the investigator's judgment, may confound the assessment;\n2. Known history of allergy to the investigational drug components, or to other drugs with similar chemical structures, or to any excipients;\n3. Prior use of pregabalin ≥ 300 mg\u002Fday, gabapentin ≥ 1200 mg\u002Fday, or mirogabalin ≥ 30 mg\u002Fday with lack of clinical efficacy as judged by the investigator;\n4. Severe liver or kidney function abnormalities, meeting any of the following clinical laboratory findings:\n\n1\\) Liver function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 × upper limit of normal (ULN); 2) Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m² (calculated using the simplified MDRD formula); 5. Women who are pregnant, planning to become pregnant during the study period, or currently breastfeeding; subjects who are unwilling to use reliable contraceptive measures (including condoms, spermicides, intrauterine devices, etc.) from the time of signing the ICF until 28 days after the last dose of the investigational drug; 6. Current use of IL-6 receptor blockers (e.g., tocilizumab, satralizumab); 7. History of suicidal behavior or suicidal ideation; 8. Participation in any other clinical study within 30 days prior to screening; 9. The investigator determines that there are other situations in which participation in the study is inappropriate.","ALL","18 Years","75 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study is a multicenter, prospective, randomized, double-blind, placebo-controlled exploratory investigation conducted in China.",[28,29],"Neuromyelitis Optica Spectrum Disorders (NMOSD)","Neuropathic Pain",[31,32,33,34],"neuromyelitis optica spectrum disorders","Neuropathic pain","Crisugabalin","NMOSD","NOT_YET_RECRUITING","2026-07-09",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":22},"2026-06-15",{"date":43,"type":22},"2027-12-31",{"name":45,"class":46},"Tang-Du Hospital","OTHER",10,{"id":49,"slug":4,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100645370","NCT07682324","Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain","Daily, Encapsulated, Green Tea Extract (GTE) to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain","GTE","Inclusion Criteria:\n\n* 18 years of age or older.\n* Established cancer-associated neuropathic pain.\n* A baseline Douler Neuropathique 4 (DN4) patient-reported neuropathic pain questionnaire score of greater than or equal to 4.\n* A stable pain management medication regimen, with no more than a 10% change in dosage in the past 14 days prior to enrollment.\n* No known allergy to rice or rice flour (basis of placebo).\n\nExclusion Criteria:\n\n* Actively undergoing cancer treatment.\n* Symptoms and\u002For diagnosis of diabetic peripheral neuropathy.\n* Self-describe as consuming more than 3 cups of green tea or matcha beverages on a daily basis.\n* High probability of completing the study and all study-related measures\u002Factivities required by the protocol.",{"count":56,"type":22},20,[58],"PHASE1","The overall objective of this study is to test an intervention of green tea extract (GTE) to mitigate neuropathic pain in patients, specifically cancer survivors, receiving supportive palliative care. Our central hypothesis is that daily, oral, encapsulated GTE will mitigate neuropathic pain, as longitudinally measured by the validated Douleur Neuropathique 4 (DN4) and blood protein biomarkers reported to be linked to the development and\u002For chronicity of neuropathic pain.",[29,61],"Cancer Treatment",[63,53,64],"green tea extract","neuropathic pain","2026-06-26",{"date":67,"type":39},"2026-07-02",{"date":69,"type":22},"2026-09-30",{"date":71,"type":22},"2029-03-01",{"name":73,"class":46},"University of Alabama at Birmingham",1,{"id":76,"slug":4,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":74},"100638006","NCT07596823","Hematological Indices and Sympathetic Block Response in Neuropathic Pain","Hematological Inflammatory Indices as Predictors of Treatment Response to Sympathetic Nerve Blocks in Neuropathic Pain: A Prospective Observational Study","HINSPAIN","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of neuropathic pain based on clinical evaluation\n* DN4 and\u002For LANSS scores compatible with neuropathic pain\n* Undergoing sympathetic nerve block as part of routine clinical treatment\n* Availability of pre-treatment and follow-up hemogram parameters\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Active infection or acute inflammatory disease\n* Active malignancy\n* History of hematological disease\n* Immunosuppressive therapy or systemic corticosteroid use\n* Major surgery or severe trauma within the last month\n* Pregnancy or breastfeeding\n* Autoimmune or rheumatologic inflammatory disease\n* Missing follow-up data",{"count":83,"type":22},120,"3 Months","OBSERVATIONAL","This prospective observational study aims to evaluate the relationship between hematological inflammatory indices and clinical treatment response in patients with neuropathic pain undergoing sympathetic nerve block procedures as part of routine clinical care. Hematological parameters including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), aggregate index of systemic inflammation (AISI), and red cell distribution width (RDW) will be evaluated before and after treatment. The association between changes in these indices and pain outcomes will be analyzed.",[29,88],"Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4",[29,90,91],"Sympathetic Nerve","Inflammation","RECRUITING","2026-06-25",{"date":95,"type":39},"2026-06-29",{"date":97,"type":22},"2026-06-01",{"date":99,"type":22},"2027-01-31",{"name":101,"class":46},"Ankara City Hospital Bilkent",{"id":103,"slug":4,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":74},"100532738","NCT06216717","Study of the Location of Motor Cortical Stimulation Electrodes in Chronic Neuropathic Refractory Patients","Inclusion Criteria\n\n* adults\n* patient implanted with a motor cortical stimulation system for chronic neuropathic refractory pain,\n* patient with available postoperative scanner\n\nExclusion Criteria: None",{"count":108,"type":22},100,"Cortical stimulation has been used since 1991 to treat neuropathic pain. However, the underlying mechanisms are still incompletely understood and under-studied. In this protocol, the investigators aim to study the myeloarchitectonic and functional characteristics of areas activated by cortical epidural electrodes and to determine their relation to therapy response in chronic neuropathic refractory pain patients.",[29],{"date":95,"type":39},{"date":113,"type":39},"2023-11-13",{"date":115,"type":22},"2027-06-25",{"name":117,"class":46},"Centre Hospitalier Universitaire de Nice",{"id":119,"slug":4,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":74},"100571953","NCT06726954","Repetitive Transcranial Magnetic Stimulation Therapy in Spinal Cord Injury Related Neuropathic Pain","Efficacy of Repetitive Transcranial Magnetic Stimulation Therapy in Neuropathic Pain Associated With Spinal Cord Injury; Randomized Controlled Trial","Inclusion Criteria:\n\nAged 18-75 years Physician-diagnosed spinal cord injury for at least 3-months Neuropathic pain for at least 3-months Pain not attributable to any other conditions\n\nExclusion Criteria:\n\n* Having an important comorbid disease such as severe heart disease (aortic stenosis, angina, hypertrophic cardiomyopathy, uncontrolled hypertension,arrhythmia, pacemaker)\n* Neurodegenerative disease\n* Epilepsy\n* History of antiepileptic drug use\n* Cognitive dysfunction\n* Lower extremity peripheral nerve injury\n* Increased intracranial pressure or uncontrolled migraine\n* Infection on the skin in the application area.\n* Having a brain lesion or a history of drug use that will affect the seizure threshold.\n\nAny TMS-related contraindications, for example:\n\n* Pacemaker\n* Metallic implant\n* Previous seizure\n* Psychiatric disorders (excluding depression and anxiety)\n* Malignancy\n* Current pregnancy",{"count":125,"type":22},63,[127],"NA","The aim of our study is to investigate the effect of different protocols of high-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) therapy added to the rehabilitation program on neuropathic pain,depression, quality of life and quality of sleep compared to each other and placebo group in participants with spinal cord injury.",[130,29],"Spinal Cord Injuries",[132,133,29],"Transcranial Magnetic Stimulation","Spinal Cord Injury","2026-06-24",{"date":65,"type":39},{"date":137,"type":39},"2024-12-16",{"date":139,"type":22},"2026-12-30",{"name":141,"class":46},"Afyonkarahisar Health Sciences University",{"id":143,"slug":4,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":148,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":159,"locationsCount":74},"100548372","NCT06420141","The Prevalence of Neuropathic Pain Pathophysiology Associated With Ankle Fracture","AFNP","Fracture Group:\n\nInclusion Criteria:\n\n1. 18-85 years old\n2. an isolated rotational ankle (AO\u002FOTA 44 types A-C) fracture that is treated operatively\n3. Abbreviated Injury Scale \\\u003C 3 for non-extremity body systems\n4. can speak, read, and understand English\n\nExclusion Criteria:\n\n1. treated for a chronic pain condition prior to their qualifying injury\n2. on a pain contract\n3. pathologic fracture\n4. Daily use of gabapentin or opiods prior to enrollment\n\nControl Group:\n\nInclusion Criteria:\n\n1. 18-85 years of age\n2. can speak, read, and understand English\n\nExclusion Criteria:\n\n1. Chronic pain or an ongoing acute pain condition\n2. Currently or have previously sustained a bone fracture\n3. Current Pain medication usage\n4. Any previous orthopaedic surgical procedures\n5. Must have been free of any surgeries for at least 5 years\n6. Peripheral neuropathy\n7. Individuals having had a major surgery or a major disease or condition, as determined by the PI, such as cardiovascular disease, metabolic disorders, renal disease, neurological disorders, or severe psychiatric conditions.",true,"85 Years",{"count":151,"type":22},250,"This application addresses the Peer Reviewed Medical Research Program Investigator-Initiated Research Award FY21 W81XWH-22-CPMRP-IIRA area of Chronic Pain Management Research Program- The investigators will utilize subjects who have sustained ankle fractures and may develop chronic pain following bone union. No attempt will be made to affect the experimental outcome in the subjects. This study will adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of research.",[29],"2026-06-23",{"date":65,"type":39},{"date":157,"type":39},"2024-01-03",{"date":43,"type":22},{"name":160,"class":46},"Indiana University",{"id":162,"slug":4,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":182,"locationsCount":74},"100535030","NCT06246526","Real-World Efficacy of Evoke® Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy in Chronic Pain Patients (ULTRA).","ULTRA","Inclusion Criteria:\n\nBe 18 years of age or older at the time of enrollment.\n\nDiagnosed with chronic, intractable pain of the trunk and\u002For limbs, which has been refractory to conservative therapy for a minimum of 6 months.\n\nSubject has a minimum Visual Analog Scale (VAS) score of 60 mm or higher (where 100 mm indicates the worst imaginable pain) at baseline.\n\nBe an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician.\n\nBe willing and capable of giving informed consent.\n\nBe willing and able to comply with study-related requirements, procedures, and visits.\n\nExclusion Criteria:\n\nSubject is pregnant or nursing.\n\nHave a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, as determined by the Investigator.\n\nHave evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention, and\u002For ability to evaluate treatment outcomes.\n\nHave an existing drug pump and\u002For SCS system or another active implantable device such as a pacemaker, deep brain stimulator (DBS), or sacral nerve stimulator (SNS).\n\nHave prior experience with SCS.\n\nBe concomitantly participating in another clinical study.",{"count":168,"type":22},50,[127],"This observational, prospective data collection is designed to evaluate the efficacy of CL-SCS therapy in real-world patients suffering from chronic pain.",[172,173,29],"Pain","Chronic Pain",[175,176],"Saluda","Spinal Cord Stimulation","2026-06-22",{"date":154,"type":39},{"date":180,"type":39},"2024-01-30",{"date":43,"type":22},{"name":183,"class":46},"Saint Francis Hospital",{"id":185,"slug":4,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":74},"100641680","NCT07660510","Evolution of Different Sensitivity Levels in Patients With Chronic Neuropathic Pain in the Pelvi-perineal Region After Treatment With High-concentration Capsaicin Patches","CAPSASENS","Inclusion Criteria:\n\n* Men or women ≥ 18 years old.\n* Patients suffering from chronic pelvi-perineal neuralgia (\\>3 months) with a DN4 score ≥4 at the inclusion visit, with or without symptoms of central sensitization, and with an indication for topical treatment with high-concentration capsaicin patch (PCHC).\n* Patients who have signed the informed consent form for the study at the inclusion visit.\n* Women must meet one of the following criteria at the time of inclusion:\n* Use adequate contraceptive measures;\n* or Be postmenopausal (aged over 50 years with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal treatments);\n* or (If aged under 50 years) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal treatments, with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal levels;\n* or Have undergone irreversible surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), with documentation of the procedure.\n\nExclusion Criteria:\n\n* Patients under guardianship, curatorship, or legal protection.\n* Pregnant or breastfeeding women.\n* Patients with contraindications to the use of the high-concentration capsaicin patch (PCHC): application on damaged skin, hypersensitivity to any of its components.\n* Patients simultaneously starting a treatment that may influence central sensitization (e.g., antidepressants, antiepileptics, psychotherapy, physical activity, transcutaneous electrical nerve stimulation).\n* Patients not affiliated with the French Social Security system.\n* Patients with insufficient cooperation and\u002For understanding to strictly comply with the protocol requirements.\n* Patients who have taken analgesics within the 12 hours prior to measurements.",{"count":191,"type":22},30,[127],"The primary objective of this study will be to demonstrate a change in pain sensitization parameters before and after the application of the high-concentration capsaicin patch.",[29,195],"Nociplastic Pain",[197,198,199,200],"Sensitization","8% capsaicin patch","Quantitative Sensory Testing","Temporal Summation",{"date":177,"type":39},{"date":203,"type":22},"2026-09-01",{"date":205,"type":22},"2028-03-01",{"name":207,"class":46},"Nantes University Hospital",{"id":209,"slug":4,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":148,"sex":17,"minAge":18,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":74},"100620882","NCT07363395","Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults","A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASCT-83 Subcutaneous Injection in Healthy Adults","Inclusion Criteria:\n\nTo participate in the study, you must:\n\n* be medically healthy based on medical history, physical exam, labs, and ECG\n* be 18-64 years (inclusive)\n* at screening, have a body mass index (BMI) \\> 19 to \\\u003C 35 kg\u002Fm²\n* be willing and able to understand and voluntarily sign an informed consent\n* Female participants of childbearing potential (women who can become pregnant) must:\n\n  1. agree to follow the study contraceptive requirements from screening through 28 days after the final dose of study drug.\n  2. agree to undergo pregnancy testing, including a negative pregnancy test at screening and at admission.\n  3. agree not to donate ova (eggs) from screening through 28 days after the final dose of study drug.\n* Male participants must:\n\n  1. have a vasectomy greater than 6 months prior to screening or be willing to follow the contraceptive requirements from screening through 90 days after final study drug administration\n  2. agree to be willing to abstain from sperm donation from screening through 90 days after final study drug administration\n\nExclusion Criteria:\n\nYou cannot participate in the study if you:\n\n* are a study site staff, Alcamena employee or immediate family member, or have participated in another clinical trial within 30 days or 5 half-lives of a prior investigational product.\n* have evidence of liver disease or abnormal liver tests (ALT\u002FAST, Alk Phos, GGT, or bilirubin \\> ULN); positive hepatitis B or C serology (people with Gilbert syndrome may be included).\n* have a history of kidney disease, protein in the urine or reduced kidney function based on screening blood tests.\n* have a history of cancer with active disease, suspected relapse, treatment within 6 months, or ongoing therapy affecting immune, liver, or kidney function.\n* have a history of heart disease, including abnormal heart rhythm, heart attack, long QT syndrome, or abnormal heart rhythm findings on screening ECG, or a family history of sudden unexplained death.\n* are currently receiving medications that affect or suppress the immune system, including steroids given by any route.\n* have a known autoimmune condition (such as lupus, rheumatoid arthritis, sarcoidosis, or vitiligo), even if it is not being treated.\n* have a positive HIV test at screening or a history of immune deficiency.\n* have abnormal blood tests suggesting ongoing inflammation\n* have an active infection or is currently being treated for an infection.\n* have a skin condition that could interfere with study skin assessments (such as psoriasis).\n* are allergic or sensitive to the study drug or its ingredients.\n* have a history of alcohol or drug abuse or addiction within the past five years, have a positive drug or alcohol test at screening, or have smoked within one month before screening.\n* have a serious mental health condition, such as major depression, schizophrenia, severe anxiety, eating disorders, severe attention deficit disorder, personality disorders, or suicidal thoughts or behavior within the past five years that could affect safety or study participation.\n* have low blood pressure upon standing, defined as a significant drop in blood pressure when moving from lying down to standing during screening or baseline testing.\n* have abnormally low white blood cell counts or neutrophil counts, unless this finding is due to a known benign condition such as benign ethnic neutropenia.","64 Years",{"count":216,"type":22},72,[58],"The goal of this clinical trial is to learn if ASCT-83 is safe and well-tolerated and measure how ASCT-83 is absorbed, distributed, and eliminated from the body over time. The study will be conducted in healthy adults.\n\nThe main questions this study will answer are:\n\n* Is ASCT-83 safe at clinical doses?\n* Does ASCT-83 have side effects at clinical doses?\n* How is ASCT-83 absorbed, distributed, and eliminated from the body? Researchers will compare ASCT-83 to a placebo (a look-alike substance that contains no drug).\n\nThe study has two parts: participants in Part 1 will receive only one dose of ASCT-83 or placebo participants in Part 2 will receive one dose of ASCT-83 or placebo a day for 7 days. Participants will visit the clinic to take ASCT-83 or placebo, to receive health checkups and undergo health tests. Participants in Part 1 will spend 5 days\u002F4 nights in the clinic, participants in Part 2 will spend 11 days\u002F10 nights in the clinic. In addition, there will be up to 3 outpatient visits.\n\nThe results of this study will help determine safe dose levels and support the design of future clinical trials.",[29],[29,221,222,223,224,225,226,227,228,229,230,231,232],"Nerve Regeneration","Analgesic","CTDSP1 Inhibitor","REST (RE1-silencing transcription factor)","Macrocyclic Peptide","Target Engagement","First-in-Human (FIH)","SAD\u002FMAD","Healthy Volunteers","Pharmacokinetics (PK)","Diabetic Peripheral Neuropathy (DPN)","Peripheral Nerve Injury (PNI)",{"date":234,"type":39},"2026-06-16",{"date":236,"type":39},"2026-01-06",{"date":238,"type":22},"2026-12-01",{"name":240,"class":241},"Alcamena Stem Cell Therapeutics","INDUSTRY",{"id":243,"slug":4,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":248,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":74},"100523217","NCT06092749","Chronic Unilateral Lumbar Radicular Pain","Effectiveness of Transgrade vs Interlaminar Epidural Steroid Injection for Chronic Unilateral Lumbar Radicular Pain","Inclusion Criteria:\n\n* \\> 6-month history of persistent pain in one leg with back pain.\n* Capable of giving informed consent.\n* Unsatisfactory response to conventional treatments including physical therapy or medications with a numeric rating scale (NRS) ≥ 5.\n\nExclusion Criteria:\n\n* Previous lumbar spinal surgery.\n* Myelopathy.\n* Rheumatoid disorders.\n* Psychiatric disorders\n* Bleeding or coagulation disorders","21 Years",{"count":250,"type":22},80,[127],"Chronic neuropathic lumbar pain is among one of the most widespread complaints of patients.Many approaches have been attempted to target chronic pain, with varying efficacy and risks. Transgrade (TG) epidural injection is a new technique using a Racz- Coudé needle for epidural access at a \"transgrade\" angle without requiring any specialized hardware or accessories. Interlaminar (IL) epidural steroid injection (ESI) is one of the procedures that involves the delivery of injectate to the epidural space through directing a needle between the laminae of two adjacent vertebrae.",[29],"2026-06-12",{"date":41,"type":39},{"date":257,"type":39},"2023-11-01",{"date":259,"type":22},"2026-07-31",{"name":261,"class":46},"Ain Shams University",{"id":263,"slug":4,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":17,"minAge":269,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":47},"100515935","NCT05997979","Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children","Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch for the Treatment of Chronic Postsurgical or Post-traumatic Neuropathic Pain: a Randomized Placebo Controlled Study in Children Aged 12 to 17-y","CAPSAPED","Inclusion Criteria:\n\n* Children aged 12 to 17 years (lower age limit of 12 has been chosen to ensure NPSI full filling).\n* Male or female.\n* Persistent neuropathic pain more than 3 months after surgery or trauma despite treatment following recommendations.\n* Neuropathic pain is defined as a DN4 score equal to or greater than 3\u002F7 or 4\u002F10, and localized in a nerve territory explained by the surgery or the trauma.\n* Treatment, survey and follow up must be realized in an identified investigating center of the study\n* For patients of childbearing potential: use of an adequate method of contraception\\* during the course of the study through 48 hours after the last patch application (girls of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to the first patch application).\n\n  * Adequate contraception includes sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide, combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)\n\nExclusion Criteria:\n\n* Intellectual deficiency not allowing full filling of NPSI.\n* Insufficient command of the French language to full fill NPSI and other evaluation tools.\n* Parents' refusal of consent.\n* Minor patients' opposition.\n* Underlying neurological disease.\n* Ongoing neurotoxic treatment.\n* Already treated by capsaicin.\n* Cutaneous lesion on pain area.\n* Patient presenting a pain area on the face, above the hairline of the scalp, and\u002For in proximity to mucous membranes\n* Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of Qutenza SmPC.","12 Years","17 Years",{"count":272,"type":22},46,[274],"PHASE3","This study concerns children aged to 12 to 17-years with local chronic neuropathic pain after trauma or surgery.\n\nIt is a multicentric randomized controlled superiority trial in parallel arms :\n\n* experimental arm: Capsaicin 8% cutaneous patch\n* controlled arm : Hydrocolloid dressing\n\nTreatment with capsaicin application is realized at baseline, and repeated 3 months after the first patch application if needed.\n\nTolerance is assessed during each application and by phone call in following days until stop of cold need.\n\nEfficacy is assessed monthly by clinical consultation until the end of the study (month 4).",[29,173],[29,278,279,280],"Pediatric","Capsaicin","Randomized clinical trial",{"date":41,"type":39},{"date":283,"type":39},"2024-03-05",{"date":285,"type":22},"2028-07-05",{"name":287,"class":46},"University Hospital, Brest",{"id":289,"slug":4,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":297,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":74},"100454358","NCT05196503","Efficacy of an Intraoperative Periradicular Application of Platelet Rich Fibrin (PRF) on the Intensity of Residual Post-surgical Neuropathic Pain After a Surgery for Disc Herniation","Efficacy of Platelet Rich Fibrin in the Prevention of Residual Neuropathic Pain Following Disc Herniation Surgery","NeuroPRF","Inclusion criteria:\n\n* Patient, male or female, \\>18 years old at the time of signing informed consent;\n* Patient for whom a diagnosis of radiculopathy on lumbar disc herniation has been made, and for whom surgery has been scheduled in the Neurosurgery department;\n* Patient affiliated to a social security health insurance scheme;\n* Patient able to understand the objectives and risks of research and to give informed, dated and signed consent;\n* Patient having been informed of the results of the prior medical examination;\n* Women of childbearing age provided that a negative blood pregnancy test is recorded at the inclusion visit and effective contraception used throughout the study.\n\nExclusion criteria:\n\n* Patient with a history of lumbar spinal surgery (multiple herniated discs, herniated disc other than lumbar);\n* Patient with HIV, active cancer, HBV, HCV (verified by interview);\n* Patient on long-term systemic corticosteroid therapy;\n* Patient with an ASA score \\> 3 during the consultation with the anesthesiologist;\n* Inability to give the patient informed information (patient in an emergency or life-threatening situation, difficulties in understanding);\n* Patient in exclusion period (determined by a previous or ongoing study);\n* Subject under safeguard of justice;\n* Subject under curatorship;\n* Pregnancy;\n* Breastfeeding.",{"count":296,"type":22},60,[274],"The prevalence of post-surgical lumbar neuropathic radiculopathy is approximately 30%. Poor response to the treatments recommended for neuropathic pain, namely antidepressants and\u002For gabapentinoids, requires the development of new techniques to prevent this chronic pain. Certain well-tolerated techniques, such as the administration of plasma enriched with platelets and fibrin (PRF), are increasingly used in regenerative medicine for their anti-inflammatory and analgesic properties. Thus, a periradicular intraoperative application of PRF may have an analgesic effect on the intensity of residual postsurgical neuropathic pain after disc herniation surgery.",[29,300],"Chronic Postsurgical Pain",[32,302,303,304],"Chronic postsurgical pain prevention","Intraoperative platelet rich fibrin","Disc herniation surgery","2026-06-05",{"date":307,"type":39},"2026-06-08",{"date":309,"type":39},"2022-02-23",{"date":311,"type":22},"2028-01",{"name":313,"class":46},"University Hospital, Strasbourg, France",{"id":315,"slug":4,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":17,"minAge":320,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":23,"phases":324,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":74},"100613310","NCT07264920","Pediatric Electrocutaneous Analgesia for Children Experiencing Neuropathic Pain","PEACE-NP","Inclusion Criteria:\n\n* Able to verbalize pain scores\n* Oncology patients with acute and\u002For chronic pain\n\nExclusion Criteria:\n\n* Patients with Implantable Devices\n* Epilepsy\n* Pregnancy\n* A history of myocardial infarction or ischemic heart disease within the past six months\n* History of severe heart arrhythmia or equivalent heart disease\n* Open Wounds or Infections at site of electrode placement\n* A history of intolerance to transcutaneous electronic nerve stimulation","5 Years","26 Years",{"count":323,"type":22},70,[127],"This is a study evaluating the Scrambler Therapy device as a non-invasive treatment for neuropathic pain in pediatric oncology patients with metastatic bone disease. The primary goal is to assess changes in pain intensity and medication use, aiming to improve quality of life and reduce reliance on systemic pain medications.",[29,173],[328,329,64],"pediatric oncology","chronic pain","2026-06-04",{"date":305,"type":39},{"date":333,"type":22},"2026-08",{"date":335,"type":22},"2030-01",{"name":337,"class":46},"Johns Hopkins University",{"id":339,"slug":4,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":23,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":74},"100643267","NCT07636980","Empowered Relief for Caregivers","Empowered Relief for Caregivers (ER-CY): A Co-Designed Brief Intervention to Support Families of Youth With Chronic Pain","ER-CY","Inclusion Criteria:\n\n* Caregiver of a youth with a chronic pain diagnosis (\\>3 months in duration)\n* English speaking\n\nExclusion Criteria:\n\n* Significant psychosocial complexity based on clinical team assessment (e.g., severe depression\u002Fanxiety, unable to tolerate a group setting)",{"count":250,"type":22},[127],"This study is testing a new program called Empowered Relief for Caregivers (ER-CY), designed to support caregivers of children and teens who live with chronic pain. ER-CY is a single two-hour class delivered online. It teaches skills for managing the stress of caring for a child in pain and for responding to a child's pain in helpful ways.\n\nUp to 80 caregivers of youth with chronic pain will take part in one ER-CY class and then complete surveys and a short interview over the following three months. The researchers want to learn two things: whether caregivers are willing and able to take part and find the program helpful and satisfying, and whether the program lowers caregiver distress and improves their child's day-to-day functioning. What is learned will help guide future programs and care for youth with chronic pain and their families.",[173,349,350,29,351,352],"Musculoskeletal Pain","Fibromyalgia","Complex Regional Pain Syndromes (CRPS)","Abdominal Pain (AP)","2026-06-03",{"date":355,"type":39},"2026-06-09",{"date":357,"type":22},"2026-10",{"date":359,"type":22},"2028-09",{"name":361,"class":46},"Stanford University",{"id":363,"slug":4,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":371,"conditions":372,"keywords":375,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":74},"100642849","NCT07634796","Development of a Pain Rehabilitation Program for Chronic Pain After SCI","Feasibility of a New Digital Pain Rehabilitation Program for People With SCI","Inclusion Criteria:\n\n* two years since injury\n* Stable pain medication?\n\nExclusion Criteria:\n\n* severe cognitive impairment\n* Alcohol or drug abuse\n* does not understand Swedish",{"count":369,"type":22},32,[127],"Pain rehabilitation programs are essential for optimal treatment of chronic pain and are usually based on the biopsychosocial model. This is, however, not standard care for people with chronic pain after a spinal cord injury (SCI) due to a biomedical focused perspective of SCI and lack of adapted programs.\n\nThe aims of this feasibility study:\n\n1. Develop a new digital pain rehabilitation program, adapted for the needs of people living with an SCI.\n2. To investigate the feasibility and acceptability of a new digital pain rehabilitation program.",[130,173,29,373,374],"Interprofessional Team Collaboration","Pain Management",[376,377],"participatory design","feasibility study","2026-06-02",{"date":355,"type":39},{"date":381,"type":22},"2026-10-01",{"date":383,"type":22},"2027-09",{"name":385,"class":46},"Umeå University",{"id":387,"slug":4,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":74},"100501596","NCT05811312","Brain Connectivity Changes With Spinal Cord Stimulation and Treatment of Chronic Pain: A Resting State NIRS\u002FEEG Study","Brain Connectivity Changes With Spinal Cord Stimulation Treatment of Chronic Pain: A Resting State NIRS\u002FEEG Study","Inclusion Criteria:\n\n* 18 years of age and a US veteran\n* Diagnosis of chronic neuropathic pain.\n* Current patient at Cleveland VA Medical Center receiving care via Pain Medicine Center.\n* Current user of tonic parasthesia-based SCS (pain relief 50% according to NPRS) or undergoing trial SCS period as part of clinical care.\n* Able to provide informed consent.\n* Medically and psychologically stable.\n\nExclusion Criteria:\n\n* Metal in the skull or deformity of the skull\n* Pregnancy or pregnancy planning during the study period.\n* Unable to provide informed consent.",{"count":393,"type":22},40,"This study aims to assess how use of spinal cord stimulation for the treatment of chronic pain impacts brain structure and function. The investigators will use a non-invasive neuroimaging technique called resting state Near Infrared Spectroscopy and Electroencephalography (rs-fNIRS\u002FEEG). The investigators will enroll Veterans who are currently receiving care at the Medical Center and who are either long term users of SCS for the treatment of their chronic pain or being evaluated for use of SCS to treat their pain.",[29],[329,64,397,398,399],"spinal cord stimulation","fNIRS","electroencephalography","2026-05-27",{"date":97,"type":39},{"date":403,"type":39},"2023-07-01",{"date":405,"type":22},"2027-06-30",{"name":407,"class":408},"VA Office of Research and Development","FED",{"id":410,"slug":4,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":415,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":418,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":4},"100640707","NCT07587255","Efficacy of Extracorporeal Shockwave Therapy on Plantar Fasciitis in Patients With Peripheral Neuropathy","Efficacy of Extracorporeal Shockwave Therapy for Plantar Fasciitis in Patients With Peripheral Neuropathy: A Clinical Evaluation","Inclusion Criteria:\n\n* Age 18 or older and 90 or younger.\n* Ability to give informed consent.\n* Presence of peripheral neuropathy, confirmed by clinical symptoms, nerve\n* conduction study, autonomic function test, quantitative sensory test, or skin biopsy.\n* Plantar fasciitis presenting as (1) heel pain persisting for more than 3 months, most noticeable with initial steps after a period of inactivity, but also worse following prolonged weight-bearing, and (2) pain with palpation of the proximal insertion of the plantar fascia.\n\nExclusion Criteria:\n\n* Presence of severe systemic diseases, including severe ischemic heart disease or congestive heart failure (left ventricular ejection fraction \\\u003C 30%), severe lung diseases with dyspnea, severe generalized edema, uncontrolled diabetes, and systemic infection.\n* Presence of severe peripheral vascular disease.\n* Presence of an implanted cardiac pacemaker, deep brain stimulator, or metallic implants (for example, internal fixation plates, screws, etc.) within the affected foot or ankle.\n* Presence of ruptured or pre-ruptured tendons in the target area. A diagnostic softtissue ultrasound of the plantar foot will be performed to assess tissue integrity if any of the following clinical red flags are identified: localized soft-tissue swelling or ecchymosis; physical examination findings indicative of a loss of continuity or tension in the plantar fascia; a history of local corticosteroid injection within the past 12 months; or a history of surgical intervention involving the affected foot.\n* Complete loss of vibration and pinprick sensation at the target area due to neuropathy, or the presence of severe mechanical allodynia (pain evoked by friction or pressure) at the target area with an intensity score of 8 or higher on the Numeric Rating Scale (NRS), where 0 represents no pain and 10 represents the most severe pain.\n* Pregnancy.\n* Coagulation disorders (including localized thrombosis in the target area).\n* Patients currently receiving anticoagulant therapy.\n* Presence of localized tumors or active bacterial and\u002For viral infections in the target area.\n* Patients who have received corticosteroid injections within the past 6 weeks in the target area.\n* Inability to give informed consent.","90 Years",{"count":417,"type":22},114,[419],"PHASE2","This study aims to evaluate the efficacy of extracorporeal shockwave therapy (ESWT) in reducing pain and improving functional outcomes for patients with neuropathy-associated plantar fasciitis.",[29,422],"Plantar Fasciitis",[64,424],"peripheral neuropathy","2026-05-12",{"date":427,"type":39},"2026-05-14",{"date":429,"type":22},"2026-05",{"date":431,"type":22},"2032-05",{"name":433,"class":46},"National Taiwan University Hospital",{"id":435,"slug":4,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":442,"briefSummary":443,"conditions":444,"keywords":448,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":461,"locationsCount":74},"100630864","NCT07493213","USG-Guided Shoulder Injections in Frozen Shoulder","Effectiveness of USG-Guided Shoulder Injections as an Adjunct to a Home Exercise Program in the Conservative Management of Painful Frozen Shoulder and Its Association With Pain Phenotypes","Inclusion Criteria:\n\nAge between 18 and 75 years and willingness to participate in the study\n\nPresence of shoulder pain lasting at least 3 months and a diagnosis of primary frozen shoulder\n\nPain intensity ≥ 4\u002F10 on the Visual Analog Scale (VAS), resistant to medical treatment\u002Fanalgesics\n\nRestriction of ≥30 degrees in at least two planes of shoulder motion (flexion, abduction, or external rotation)\n\n\\-\n\nExclusion Criteria:\n\n* History of shoulder trauma\n\nPresence of neurological conditions such as stroke, brachial plexus injury, Parkinson's disease, or cervical spine pathology with or without radiculopathy\n\nHistory of shoulder surgery, shoulder malignancy or tumor, or prior shoulder manipulation\n\nPresence of shoulder arthritis, rotator cuff tear, other shoulder injuries, or thoracic outlet syndrome\n\nSystemic diseases affecting the shoulder, severe degeneration or trauma (e.g., osteoarthritis, rheumatoid arthritis, labral or articular cartilage injuries), or inflammatory rheumatic diseases\n\nSteroid injection to the affected extremity within the last 3 months, use of oral steroids or NSAIDs, or ongoing surgical\u002Finterventional treatment\n\nPregnancy or lactation\n\nUncontrolled diabetes, heart failure, or uncontrolled systemic diseases (e.g., liver failure, chronic kidney disease, significant endocrine disorders)\n\nCommunication problems or severe psychiatric disorders",{"count":441,"type":22},68,[127],"Frozen shoulder (adhesive capsulitis) is characterized by pain and a progressive restriction of both active and passive shoulder range of motion, significantly impairing daily activities and quality of life. This study aims to evaluate the effectiveness of USG-guided shoulder injections, when added to a home-based exercise program, in the conservative management of patients with chronic, painful frozen shoulder.\n\nIn this prospective randomized study, patients diagnosed with painful frozen shoulder will be included. In addition to a standardized home-based exercise program, patients will receive either USG-guided suprascapular nerve block alone or a combination of suprascapular nerve block and subacromial injection. The effects of these approaches on clinical outcomes will be assessed over a 20-week follow-up period.\n\nPrimary outcome measures include pain intensity assessed by the Visual Analog Scale (VAS), functional status evaluated by the Shoulder Pain and Disability Index (SPADI), and shoulder range of motion. Secondary outcomes include depression level (Beck Depression Inventory), sleep quality, pain phenotype (nociplastic, neuropathic, or nociceptive), hand grip strength, ultrasonographic findings ( (coracohumeral ligament thickness, subacromial bursa thickness) , and patient satisfaction (subjective impression of improvement).\n\nThe results of this study are expected to provide evidence on the comparative effectiveness and additional benefits of different shoulder injection approaches when combined with home-based exercise therapy in patients with chronic frozen shoulder.",[445,446,447,195,29],"Frozen Shoulder","Adhesive Capsulitis","Shoulder Pain",[445,446,449,450,447,451,452,453,454,455],"Shoulder Injection","Home Exercise Program","Range of Motion","SPADI","Ultrasound-Guided Injection","pain phenotypes","exercises","2026-05-11",{"date":427,"type":39},{"date":459,"type":39},"2026-04-01",{"date":405,"type":22},{"name":462,"class":463},"Konya Beyhekim Training and Research Hospital","OTHER_GOV",{"id":465,"slug":4,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":472,"conditions":473,"keywords":475,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":482,"leadSponsor":484,"locationsCount":74},"100630865","NCT07493226","Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis","Comparative Efficacy of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) With Distinct Chemical Structures in Shoulder Adhesive Capsulitis and the Role of Pain Phenotypes","Inclusion Criteria:\n\n1. Being between 18-75 years of age\n2. Having shoulder pain that has lasted for at least one month and being diagnosed with primary frozen shoulder\n3. Having a VAS pain level ≥ 4\u002F10\n4. Having ≥30 degrees of range of motion restriction in at least two planes (flexion, abduction, or external rotation)\n5. Not having any exclusion criteria and agreeing to participate in the study voluntarily\n\nExclusion Criteria:\n\n1. Patients with a history of shoulder trauma, those with musculoskeletal disorders characterized by pain and loss of function in the affected extremity (such as lateral epicondylitis, flexor tendon injury, de Quervein's tenosynovitis)\n2. Presence of neurological involvement such as stroke, brachial plexus injury, Parkinson's disease, and cervical spine injury with or without radiculopathy\n3. History of shoulder surgery, malignancy or tumor in the shoulder, those who have undergone shoulder manipulation\n4. Presence of shoulder arthritis, rotator cuff tear or other shoulder injuries, thoracic outlet syndrome\n5. Systemic disease affecting the shoulder region, severe degeneration or trauma (e.g., osteoarthritis, rheumatoid arthritis, history of labrum or articular cartilage injuries), inflammatory rheumatic diseases\n6. Those who have received steroid injections into the affected extremity within the last 3 months, those using oral steroids or NSAIDs, those receiving any surgical or interventional treatment, or Planned individuals:\n7. Those who are pregnant or lactating\n8. Those with uncontrolled diabetes, heart failure, uncontrolled systemic disease (liver disease, chronic kidney failure, significant endocrine disorders, etc.)\n9. Those with communication problems, severe psychiatric disorders\n10. Those allergic to NSAIDs or with any contraindications\n11. Those with bleeding, coagulation disorders, stomach ulcers, or symptomatic gastritis",{"count":83,"type":22},[127],"Patients aged 18-75 years who present to a tertiary rehabilitation hospital with shoulder pain and restricted range of motion, and who consent to participate, will be included in the study. Eligibility will be determined based on predefined inclusion and exclusion criteria.\n\nEligible patients will be randomly assigned to receive one of several nonsteroidal anti-inflammatory drugs (NSAIDs) with differing chemical properties (e.g., diclofenac, meloxicam, or indomethacin), in combination with a home-based exercise program for shoulder adhesive capsulitis. Patients' sociodemographic data, as well as detailed clinical and examination findings and baseline outcomes, will be recorded. Patients will be informed about their condition, and modifications to activities of daily living will be recommended.Patients' pain phenotypes (nociceptive, neuropathic, nociplastic) will be categorized based on clinical history and questionnaires, and it will be determined which pain types derive greater benefit from NSAIDs.\n\nFollow-up assessments will be conducted at the end of the first and second weeks. At the first-week follow-up, pain intensity will be evaluated using the Visual Analog Scale (VAS). If the treatment is deemed effective (defined as a ≥3-point reduction or ≥50% decrease in VAS), the same NSAID will be continued for an additional week; otherwise, it will be switched to an alternative NSAID with a different biochemical profile (group). The outcomes assessments will be performed by a blinded evaluator to minimize bias.",[445,446,447,474,195,29],"NSAID (Non-Steroidal Anti-Inflammatory Drug)",[476,477,478,454,455,479],"frozen shoulder","adhesive capsulitis","shoulder pain","Nonsteroidal Anti-Inflammatory Drugs",{"date":427,"type":39},{"date":459,"type":39},{"date":483,"type":22},"2027-03-30",{"name":462,"class":463},{"id":486,"slug":4,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":148,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":74},"100501163","NCT05805683","Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury","Effect of Early Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury","Inclusion Criteria:\n\n* Patients aged ≥18 years, with spinal cord injury at any level and any degree of completeness in the early stage of trauma.\n\nExclusion Criteria:\n\n* Intake of anticonvulsants medications.\n* Evidence of neuropathic pain.\n* Evidence of previous allergic reaction to calcitonin.\n* Patients with renal, hepatic and cardiac dysfunction or neurological disorders .\n* brain damage or major trauma to extremities or abdomen.",{"count":492,"type":22},126,[127],"This prospective randomized double blinded study will be conducted to evaluate the effect of early pharmacologic intervention with calcitonin on the incidence or the severity of neuropathic pain after spinal cord injury",[496,29,133],"Calcitonin",[496,32,498],"Spinal cord injury",{"date":427,"type":39},{"date":501,"type":39},"2023-05-01",{"date":503,"type":22},"2028-05-01",{"name":505,"class":46},"Tanta University",{"id":507,"slug":4,"hasResults":11,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":23,"phases":513,"briefSummary":514,"conditions":515,"keywords":516,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":525,"leadSponsor":527,"locationsCount":74},"100637499","NCT07588711","Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury","Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) as an Anti-inflammatory Strategy for the Treatment of Neuropathic Pain Following Spinal Cord Injury","Inclusion Criteria:\n\n* SCI of any level or severity\n* 18 years of age or older\n* current neuropathic pain\n* on no medications or on a stable prescribed dose (no change in prior 6-weeks) of anti-inflammatory, pain medications and\u002For depression medications\n\nExclusion Criteria:\n\n* Prone to autonomic dysreflexia\n* presence of cardiovascular disease\n* pacemaker or other implanted electrical device\n* cerebral shunts\n* epilepsy\n* pregnant or attempting to become pregnant\n* current wound\u002Finfection\n* unstable dose of prescribed anti-inflammatory, depression, or pain medications within past 6-weeks.",{"count":369,"type":22},[127],"This pilot randomized, double-blind, sham-controlled clinical investigation will evaluate the feasibility and safety of a 30-day home-based transcutaneous auricular vagus nerve stimulation (taVNS) intervention in adults with spinal cord injury (SCI) and neuropathic pain. Participants will be randomized to receive either active taVNS targeting the auricular branch of the vagus nerve or sham taVNS delivered to the earlobe. Primary outcomes include feasibility, safety, adherence, acceptability, and blinding success. Exploratory outcomes include changes in neuropathic pain, systemic inflammatory biomarkers, vagal tone assessed via heart rate variability, and quality of life.",[133,29],[517,518,519,64,520],"vagus nerve stimulation","inflammation","spinal cord injury","taVNS","2026-05-07",{"date":523,"type":39},"2026-05-15",{"date":381,"type":22},{"date":526,"type":22},"2028-08-30",{"name":528,"class":46},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":530,"slug":4,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":536,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":543,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":549,"leadSponsor":551,"locationsCount":74},"100637464","NCT07579611","Efficacy of Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathy","Efficacy of Posterior Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathic Pain: A Multicenter Randomized Crossover Trial","CHEMOSTIM","Inclusion Criteria:\n\n1. Adult patient with chemotherapy-induced painful neuropathy (platinum salts, vincristine, taxanes, alkaloids, epothilone, thalidomide, etc.) evolving for at least 1 year\n2. Indication for spinal cord stimulation validated by a multidisciplinary team meeting according to SFETD\u002FSFNM guidelines\n3. Resistance to pharmacological or topical treatment (failure of at least two therapeutic lines or intolerable side effects: anticonvulsants, antidepressants, capsaicin, etc.)\n4. Pain score \\> 5\u002F10 on numerical scale in the lower limbs\n5. Patient able to understand and give informed consent to the protocol\n6. Patient affiliated to the French Social Security system\n7. Patient able to complete follow-up questionnaires\n\nExclusion Criteria:\n\n* 1\\. Contraindication to spinal cord stimulation:\n* Extensive laminectomy\n* Coagulopathy\n* Intercurrent infections\n* Psychiatric disorders\n\n  2\\. Body Mass Index (BMI) \\> 40\n\n  3\\. Life expectancy \\\u003C 1 year\n\n  4\\. Ongoing pregnancy\n\n  5\\. Patient under guardianship or curatorship\n\n  6\\. Patient already implanted with a spinal cord stimulation device","100 Years",{"count":441,"type":22},[127],"Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and debilitating side effect of many cancer treatments. It affects 28 to 48% of patients receiving chemotherapy. Symptoms include tingling, numbness, burning sensations, and pain mainly in the hands and feet. While CIPN often improves after chemotherapy ends, in some patients the pain persists and becomes chronic, severely impairing quality of life, sleep, and daily functioning.\n\nCurrently, no treatment has been shown to prevent CIPN. For patients with chronic pain, duloxetine is the only recommended drug, but its efficacy is limited. When standard medications fail, patients have very few options.\n\nSpinal cord stimulation (SCS) is a well-established neurosurgical technique used to treat various forms of chronic neuropathic pain, including pain after surgery, trauma, or diabetes. In this procedure, thin electrodes are placed in the epidural space near the spinal cord and connected to a small implantable pulse generator. The electrical impulses delivered by the device modulate pain signals in the nervous system.\n\nPreliminary case reports suggest that SCS may be effective in patients with CIPN, but no randomized controlled trial has yet established its value in this specific indication. The CHEMOSTIM study aims to fill this gap.\n\nCHEMOSTIM is a multicenter, prospective, randomized crossover trial. All enrolled patients will undergo SCS implantation. Participants will then be randomized to receive either active stimulation first followed by sham stimulation, or sham stimulation first followed by active stimulation. In the sham phase, the device is implanted but switched off following a simulated programming session, so patients cannot tell which phase they are in.\n\nThe primary outcome is the proportion of patients achieving more than 50% pain reduction on a Visual Analog Scale (VAS) during the active stimulation phase compared to the sham stimulation phase, assessed at 4 months.\n\nSecondary outcomes include changes in quality of life, anxiety and depression, sleep quality, medication use, individualized goal attainment, neurological examination, and nerve conduction studies. The study will also evaluate post-stimulation effects and complications.\n\nEligible patients are adults with chronic CIPN evolving for at least one year, with pain greater than 5\u002F10 in the lower limbs, who have failed at least two lines of pharmacological treatment (antidepressants, anticonvulsants, topical agents, etc.) and whose indication for SCS has been validated by a multidisciplinary team following SFETD\u002FSFNM guidelines.",[29,541,542],"Chemotherapy-induced Peripheral Neuropathy (CIPN)","Cancer-related Pain",[397,544,64,545],"posterior cord stimulation","Chemotherapy-induced neuropathy","2026-05-06",{"date":425,"type":39},{"date":203,"type":22},{"date":550,"type":22},"2029-05-01",{"name":552,"class":46},"Assistance Publique Hopitaux De Marseille",{"id":554,"slug":4,"hasResults":11,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":560,"targetDuration":4,"studyType":23,"phases":561,"briefSummary":562,"conditions":563,"keywords":568,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":4},"100636768","NCT07569978","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate the Efficacy and Safety of Topical 10% High-Concentration 35 kDa Hyaluronan (HA35) Gel in Subjects With Herpes Zoster-Associated Pain","HA35-HZ","Inclusion Criteria:\n\n* Age 18-85 years, male or female\n* Clinically diagnosed with herpes zoster-associated pain (acute ZAP or PHN)\n* Baseline pain NRS score ≥5\n* Ability to understand and complete NRS assessments\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Acute bacterial skin infection at the application site\n* Use of topical analgesics or antiviral therapy within 24 hours\n* Systemic analgesic use within 6 hours\n* Known hypersensitivity to hyaluronan or gel components\n* Pregnant or lactating women\n* Severe systemic disease or malignant tumor",{"count":191,"type":22},[127],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with herpes zoster-associated pain (ZAP). Eligible participants will receive a single topical application of the study gel. The primary objective is to assess rapid pain reduction within 2 minutes and 24hours after application. Secondary objectives include evaluation of analgesic duration, local tolerability, erythema improvement, and overall safety throughout the observation period. This is a minimal-risk, non-pharmacological supportive care intervention.",[564,565,566,29,567],"Herpes Zoster","Zoster-Associated Pain","Postherpetic Neuralgia","Acute Pain",[569,570,571,572,564,573,566,29,574,575,576],"Hyaluronan","35 kDa Hyaluronan","HA35","Topical Gel","Zoster Pain","Analgesia","Non-pharmacological Intervention","Pilot Clinical Study","2026-05-05",{"date":579,"type":39},"2026-05-08",{"date":581,"type":22},"2026-05-01",{"date":583,"type":22},"2026-07-10",{"name":585,"class":241},"Nakhia Impex LLC",{"id":587,"slug":4,"hasResults":11,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":593,"targetDuration":4,"studyType":23,"phases":595,"briefSummary":596,"conditions":597,"keywords":598,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":604,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":611},"100429062","NCT04867187","rTMS Efficacy Coupled With Mirror Therapy","Clinical Study of Repetitive Transcranial Magnetic Stimulation (RTMS) Efficacy Coupled With Mirror Therapy for Neuropathic Pain Relief","STIRM","Inclusion Criteria:\n\n* Clinical symptoms typical of neuropathic pain\n* Refractory to drug therapies\n* Lasting for at least 6 months, with a moderate to severe pain intensity (≥4\u002F10 on Visual Analog Scale, VAS) and a stable pain treatment since 1month at least\n* Having right to health benefits\n\nExclusion Criteria:\n\n* Ferromagnetic components and implanted microprocessors (i.e. cochlear implants)\n* Drug-resistant or active epilepsy, pacemaker, pregnancy, ongoing depression or personality troubles, and ongoing opioid treatment.\n* Any other contraindications to MRI scanner (e.g., claustrophobia, etc.).",{"count":594,"type":22},64,[127],"Neuropathic pain is particularly difficult to treat with classic first-line drugs. Neuromodulation techniques using repetitive transcranial magnetic stimulation (rTMS) are useful alternative, but there is a need to improve their analgesic effect.Virtual reality mirror therapy has shown the capacity to alleviate pain and may be easily coupled with rTMS.The present project will investigate in individuals with neuropathic pain the effects of the rTMS coupled with virtual reality mirror therapy.",[29],[599,600,601,602,603],"transcranial magnetic stimulation","virtual reality","mirror therapy","brain networks","predictive model",{"date":579,"type":39},{"date":606,"type":39},"2022-10-27",{"date":608,"type":22},"2027-04",{"name":610,"class":46},"Centre Hospitalier Universitaire de Saint Etienne",2,{"id":613,"slug":4,"hasResults":11,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":619,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":622,"conditions":623,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":631,"leadSponsor":633,"locationsCount":74},"100623953","NCT07403331","Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to Reduce Pain and Improve Physical Function.","Optimizing Treatment for Chronic Neuropathic Pain: A Replicated Single Case Experimental Design Evaluating a Treatment Bundle Consisting of Multidisciplinary Rehabilitation and Spinal Cord Stimulation (SCS-R)","SCS-R","Inclusion criteria:\n\n* Peripheral neuropathic pain in one or both legs for \\>6 months due to:\n\n  * (1) Post Spinal Pain Syndrome (type 1 or 2).\n  * (2) Localized nerve damage.\n* The area of the neuropathic pain in the leg(s) must be the dominant pain component.\n* Age ranges from 18-60 years.\n* Previous standard conservative (or surgical) treatment attempted.\n* Opioid use within permissible limits at implantation time (daily opioid dose \\\u003C50 mg OMEQ).\n* Willingness to actively participate in the treatment bundle.\n* Living within reasonable travelling distance from Oslo.\n* Proficiency in understanding oral and written Norwegian, essential to benefit from the program that relies on mutual comprehension, nuanced conversation, and emotional expression, which are language-dependent.\n* Cognitive capacity to provide informed consent.\n* Ability to master the technical aspects of the SCS system (switching programs on the remote control).\n\nExclusion criteria:\n\n* Currently undergoing the claims process for health benefits (e.g., disability pensions from NAV (Norwegian Labour and Welfare Administration).\n* Presenting a psychological or psychiatric disorder that may impact treatment efficacy.\n* Chronic generalized pain conditions.\n* Other pain conditions in the affected area, such as osteoarthritis.\n* Pregnancy.","60 Years",{"count":47,"type":22},[127],"People with nerve damage can develop nerve pain. The pain can sometimes be severe and unpredictable, causing odd or alarming sensations - for example, lightning-like or electric shock feelings in the area served by the damaged nerve.\n\nThe investigators will examine a treatment for nerve pain in the legs caused by nerve damage, which can occur after a herniated disc or a bone fracture, with or without surgery.\n\nPrevious research suggests that spinal cord stimulation can relieve nerve pain in the legs after surgery or injury, but its effectiveness is still debated. Other studies show that multidisciplinary treatment helps people with long-term pain to improve their quality of life and to better cope in life. National and international guidelines recommend this kind of multidisciplinary care for long-term pain.\n\nThere has yet been published research on spinal cord stimulation combined with multidisciplinary treatment as a bundle intervention. The investigators therefore want to find out whether this combined approach can reduce nerve pain in the legs and improve physical functioning.",[29,624,625,626,627],"Multidisciplinary Approach","Rehabilitation Exercise","Acceptance & Commitment Therapy","Spinal Cord Stimulation (SCS)","2026-05-04",{"date":546,"type":39},{"date":628,"type":22},{"date":632,"type":22},"2027-07-01",{"name":634,"class":46},"Oslo University Hospital",""]